Tinengotinib — Investigational Agent
FGFR Inhibitor · Phase 3 · TransThera Sciences
Mechanism of Action
Oral multi-kinase spectrum-selective inhibitor with potent activity against FGFR1–3, as well as VEGFR, JAK, and Aurora kinases. Critically, it retains activity against FGFR2 acquired resistance mutations (including gatekeeper V564F and molecular-brake mutations) that drive resistance to first-generation FGFR inhibitors such as pemigatinib and infigratinib, positioning it for FGFR-altered cholangiocarcinoma that has progressed on prior FGFR inhibitors.
Investigational Indications
- FGFR2-altered intrahepatic cholangiocarcinoma refractory to prior FGFR inhibitor
- FGFR-altered cholangiocarcinoma (chemotherapy- and FGFR inhibitor-refractory)
- Other advanced solid tumors